Indian pharma major
Ranbaxy Laboratories (Ranbaxy) has announced the day-1 launch of olanzapine
tablets, the generic version of Zyprexa. The olanzapine tablets 2.5mg, 5mg,
7.5mg and 10mg and also orodispersables in 5mg and 10mg are on company's cards.
Zyprexa is the innovator product of Eli Lilly and has a market size of $210
million as per IMS Data 2010.
The necessary
regulatory approvals have been received by Ranbaxy from the Spanish Health
authorities to manufacture and market olanzapine in Spain and will be launching
the product on day-1, following patent expiry.
An atypical antipsychotic, Olanzapine is indicated for the treatment of schizophrenia in adults. The product is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial positive response. Olanzapine is also indicated for the treatment of moderate to severe manic episodes and prevents their recurrence. It is also indicated for the treatment of Bipolar disorders.
The firm established operations in Spain in the year 2004 and now offers a wide array of pharma products that cover therapy areas such as gastrointestinals, cardiovascular, CNS and antibiotics.
An atypical antipsychotic, Olanzapine is indicated for the treatment of schizophrenia in adults. The product is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial positive response. Olanzapine is also indicated for the treatment of moderate to severe manic episodes and prevents their recurrence. It is also indicated for the treatment of Bipolar disorders.
The firm established operations in Spain in the year 2004 and now offers a wide array of pharma products that cover therapy areas such as gastrointestinals, cardiovascular, CNS and antibiotics.
No comments:
Post a Comment